Etiology and Treatment of Hypogonadism in Adolescents

Pediatric Clinics of North America

Volumn 58, Issue 5, 2011, Pages 1181-1200

  Viswanathan, Vidhya ^a   Eugster, Erica A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescents; Delayed puberty; Hypergonadotropic hypogonadism; Hypogonadotropic hypogonadism; Treatment

Indexed keywords

ANDRIO; ASPARAGINASE; CELL NUCLEUS RECEPTOR; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; LEPTIN; LEPTIN RECEPTOR; MEDROXYPROGESTERONE; MERCAPTOPURINE; METHOTREXATE; PIPERAZINE ESTRONE SULFATE; PREDNISOLONE; SEX HORMONE; TESTOPEL; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; AMENORRHEA; ANDROGEN INSENSITIVITY SYNDROME; ANDROGEN THERAPY; AUTOIMMUNITY; CONGENITAL ADRENAL HYPERPLASIA; DAX 1 GENE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; ESTROGEN THERAPY; EVENING DOSAGE; FGF1 GENE; GALACTOSEMIA; GENE; GENE MUTATION; GENITAL SYSTEM; GONAD DEVELOPMENT; GONADAL DYSGENESIS; GPR54 GENE; HESX1 GENE; HORMONE SYNTHESIS; HUMAN; HYPERGONADOTROPIC HYPOGONADISM; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; KAL 1 GENE; KALLMANN SYNDROME; KLINEFELTER SYNDROME; LEP GENE; LEPR GENE; PATHOGENESIS; PREMATURE OVARIAN FAILURE; PROP 1 GENE; PUBERTY; REVIEW; SF 1 GENE; SKIN IRRITATION; TESTICULAR REGRESSION SEQUENCE; TESTIS DISEASE; TRAUMATIC BRAIN INJURY; TURNER SYNDROME; WHOLE BODY RADIATION; X CHROMOSOME;

EID: 80053596392     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2011.07.009     Document Type: Review

References (116)

1. Boyar R., Finkelstein J., Roffwarg H., et al. Synchronization of augmented luteinizing hormone secretion with sleep during puberty. N Engl J Med 1972, 287(12):582-586.
2. Apter D., Butzow T.L., Laughlin G.A., et al. Gonadotropin-releasing hormone pulse generator activity during pubertal transition in girls: pulsatile and diurnal patterns of circulating gonadotropins. J Clin Endocrinol Metab 1993, 76(4):940-949.
3. Sedlmeyer I.L., Palmert M.R. Delayed puberty: analysis of a large case series from an academic center. J Clin Endocrinol Metab 2002, 87(4):1613-1620.
4. von Kalckreuth G., Haverkamp F., Kessler M., et al. Constitutional delay of growth and puberty: do they really reach their target height?. Horm Res 1991, 35(6):222-225.
5. Bergada I., Bergada C. Long term treatment with low dose testosterone in constitutional delay of growth and puberty: effect on bone age maturation and pubertal progression. J Pediatr Endocrinol Metab 1995, 8(2):117-122.
6. Achermann J.C., Weiss J., Lee E.J., et al. Inherited disorders of the gonadotropin hormones. Mol Cell Endocrinol 2001, 179(1-2):89-96.
7. Kohler B., Lin L., Ferraz-de-Souza B., et al. Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46, XY patients with severe underandrogenization but without adrenal insufficiency. Hum Mutat 2008, 29(1):59-64.
8. Biason-Lauber A., Schoenle E.J. Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency. Am J Hum Genet 2000, 67(6):1563-1568.
9. Muscatelli F., Strom T.M., Walker A.P., et al. Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Nature 1994, 372(6507):672-676.
10. Yang F., Hanaki K., Kinoshita T., et al. Late-onset adrenal hypoplasia congenita caused by a novel mutation of the DAX-1 gene. Eur J Pediatr 2009, 168:329-331.
11. Habiby R.L., Boepple P., Nachtigall L., et al. Adrenal hypoplasia congenita with hypogonadotropic hypogonadism: evidence that DAX-1 mutations lead to combined hypothalamic and pituitary defects in gonadotropin production. J Clin Invest 1996, 98(4):1055-1062.
12. Mantovani G., De Menis E., Borretta G., et al. DAX1 and X-linked adrenal hypoplasia congenita: clinical and molecular analysis in five patients. Eur J Endocrinol 2006, 154(5):685-689.
13. Franco B., Guioli S., Pragliola A., et al. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 1991, 353(6344):529-536.
14. Vogl T.J., Stemmler J., Heye B., et al. Kallman syndrome versus idiopathic hypogonadotropic hypogonadism at MR imaging. Radiology 1994, 191(1):53-57.
15. Oliveira L.M., Seminara S.B., Beranova M., et al. The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. J Clin Endocrinol Metab 2001, 86(4):1532-1538.
16. Sato N., Katsumata N., Kagami M., et al. Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab 2004, 89(3):1079-1088.
17. Pitteloud N., Zhang C., Pignatelli D., et al. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A 2007, 104(44):17447-17452.
18. de Roux N., Young J., Misrahi M., et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 1997, 337(22):1597-1602.
19. de Roux N., Milgrom E. Inherited disorders of GnRH and gonadotropin receptors. Mol Cell Endocrinol 2001, 179(1-2):83-87.
20. de Roux N., Genin E., Carel J.C., et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A 2003, 100(19):10972-10976.
21. Raivio T., Falardeau J., Dwyer A., et al. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 2007, 357(9):863-873.
22. Pfaffle R.W., Blankenstein O., Wuller S., et al. Combined pituitary hormone deficiency: role of Pit-1 and Prop-1. Acta Paediatr Suppl 1999, 88(433):33-41.
23. Lazar L., Gat-Yablonski G., Kornreich L., et al. PROP-1 gene mutation (R120C) causing combined pituitary hormone deficiencies with variable clinical course in eight siblings of one Jewish Moroccan family. Horm Res 2003, 60(5):227-231.
24. Dasen J.S., Barbera J.P., Herman T.S., et al. Temporal regulation of a paired-like homeodomain repressor/TLE corepressor complex and a related activator is required for pituitary organogenesis. Genes Dev 2001, 15(23):3193-3207.
25. Dattani M.T., Martinez-Barbera J.P., Thomas P.Q., et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 1998, 19(2):125-133.
26. Haddad N.G., Eugster E.A. Hypopituitarism and neurodevelopmental abnormalities in relation to central nervous system structural defects in children with optic nerve hypoplasia. J Pediatr Endocrinol Metab 2005, 18(9):853-858.
27. Pfaeffle R.W., Hunter C.S., Savage J.J., et al. Three novel missense mutations within the LHX4 gene are associated with variable pituitary hormone deficiencies. J Clin Endocrinol Metab 2008, 93(3):1062-1071.
28. Kelberman D., Rizzoti K., Avilion A., et al. Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. J Clin Invest 2006, 116(9):2442-2455.
29. Farooqi I.S., Matarese G., Lord G.M., et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002, 110(8):1093-1103.
30. Farooqi I.S., Wangensteen T., Collins S., et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007, 356(3):237-247.
31. Wharton R.H., Loechner K.J. Genetic and clinical advances in Prader-Willi syndrome. Curr Opin Pediatr 1996, 8(6):618-624.
32. Jeffcoate W.J., Laurance B.M., Edwards C.R., et al. Endocrine function in the Prader-Willi syndrome. Clin Endocrinol (Oxf) 1980, 12(1):81-89.
33. Crino A., Schiaffini R., Ciampalini P., et al. Hypogonadism and pubertal development in Prader-Willi syndrome. Eur J Pediatr 2003, 162(5):327-333.
34. Schulze A., Mogensen H., Hamborg-Petersen B., et al. Fertility in Prader-Willi syndrome: a case report with Angelman syndrome in the offspring. Acta Paediatr 2001, 90(4):455-459.
35. Akefeldt A., Tornhage C.J., Gillberg C. A woman with Prader-Willi syndrome gives birth to a healthy baby girl. Dev Med Child Neurol 1999, 41(11):789-790.
36. Morton M.V., Wehman P. Psychosocial and emotional sequelae of individuals with traumatic brain injury: a literature review and recommendations. Brain Inj 1995, 9(1):81-92.
37. Kelly D.F., Gonzalo I.T., Cohan P., et al. Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a preliminary report. J Neurosurg 2000, 93(5):743-752.
38. Lieberman S.A., Oberoi A.L., Gilkison C.R., et al. Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. J Clin Endocrinol Metab 2001, 86(6):2752-2756.
39. Benvenga S., Campenni A., Ruggeri R.M., et al. Clinical review 113: hypopituitarism secondary to head trauma. J Clin Endocrinol Metab 2000, 85(4):1353-1361.
40. Tanriverdi F., Senyurek H., Unluhizarci K., et al. High risk of hypopituitarism after traumatic brain injury: a prospective investigation of anterior pituitary function in the acute phase and 12 months after trauma. J Clin Endocrinol Metab 2006, 91(6):2105-2111.
41. Merchant T.E., Williams T., Smith J.M., et al. Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function. Int J Radiat Oncol Biol Phys 2002, 54(1):45-50.
42. Gonc E.N., Yordam N., Ozon A., et al. Endocrinological outcome of different treatment options in children with craniopharyngioma: a retrospective analysis of 66 cases. Pediatr Neurosurg 2004, 40(3):112-119.
43. Mills J.L., Fears T.R., Robison L.L., et al. Menarche in a cohort of 188 long-term survivors of acute lymphoblastic leukemia. J Pediatr 1997, 131(4):598-602.
44. Constine L.S., Woolf P.D., Cann D., et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993, 328(2):87-94.
45. Rappaport R., Brauner R., Czernichow P., et al. Effect of hypothalamic and pituitary irradiation on pubertal development in children with cranial tumors. J Clin Endocrinol Metab 1982, 54(6):1164-1168.
46. Nandagopal R., Laverdiere C., Mulrooney D., et al. Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. Horm Res 2008, 69(2):65-74.
47. Chan J.L., Mantzoros C.S. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet 2005, 366(9479):74-85.
48. Welt C.K., Chan J.L., Bullen J., et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004, 351(10):987-997.
49. Nielsen J., Wohlert M. Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Hum Genet 1991, 87(1):81-83.
50. Bondy C.A. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007, 92(1):10-25.
51. Pasquino A.M., Passeri F., Pucarelli I., et al. Spontaneous pubertal development in Turner's syndrome. Italian Study Group for Turner's Syndrome. J Clin Endocrinol Metab 1997, 82(6):1810-1813.
52. Hovatta O. Pregnancies in women with Turner's syndrome. Ann Med 1999, 31(2):106-110.
53. Fechner P.Y., Davenport M.L., Qualy R.L., et al. Differences in follicle-stimulating hormone secretion between 45, X monosomy Turner syndrome and 45, X/46, XX mosaicism are evident at an early age. J Clin Endocrinol Metab 2006, 91(12):4896-4902.
54. Bojesen A., Juul S., Gravholt C.H. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab 2003, 88(2):622-626.
55. Abulhasan S.J., Tayel S.M., al-Awadi S.A. Mosaic Turner syndrome: cytogenetics versus FISH. Ann Hum Genet 1999, 63(Pt 3):199-206.
56. Rizzolio F., Bione S., Sala C., et al. Chromosomal rearrangements in Xq and premature ovarian failure: mapping of 25 new cases and review of the literature. Hum Reprod 2006, 21(6):1477-1483.
57. Linden M.G., Bender B.G., Harmon R.J., et al. 47, XXX: what is the prognosis?. Pediatrics 1988, 82(4):619-630.
58. Lin H.J., Ndiforchu F., Patell S. Exstrophy of the cloaca in a 47, XXX child: review of genitourinary malformations in triple-X patients. Am J Med Genet 1993, 45(6):761-763.
59. Holland C.M. 47, XXX in an adolescent with premature ovarian failure and autoimmune disease. J Pediatr Adolesc Gynecol 2001, 14(2):77-80.
60. Matthews C.H., Borgato S., Beck-Peccoz P., et al. Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. Nat Genet 1993, 5(1):83-86.
61. Layman L.C., Lee E.J., Peak D.B., et al. Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone beta-subunit gene. N Engl J Med 1997, 337(9):607-611.
62. Lindstedt G., Nystrom E., Matthews C., et al. Follitropin (FSH) deficiency in an infertile male due to FSHbeta gene mutation. A syndrome of normal puberty and virilization but underdeveloped testicles with azoospermia, low FSH but high lutropin and normal serum testosterone concentrations. Clin Chem Lab Med 1998, 36(8):663-665.
63. Weiss J., Axelrod L., Whitcomb R.W., et al. Hypogonadism caused by a single amino acid substitution in the beta subunit of luteinizing hormone. N Engl J Med 1992, 326(3):179-183.
64. Furui K., Suganuma N., Tsukahara S., et al. Identification of two point mutations in the gene coding luteinizing hormone (LH) beta-subunit, associated with immunologically anomalous LH variants. J Clin Endocrinol Metab 1994, 78(1):107-113.
65. Kremer H., Kraaij R., Toledo S.P., et al. Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. Nat Genet 1995, 9(2):160-164.
66. Latronico A.C., Anasti J., Arnhold I.J., et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N Engl J Med 1996, 334(8):507-512.
67. Arnhold I.J., Latronico A.C., Batista M.C., et al. Clinical features of women with resistance to luteinizing hormone. Clin Endocrinol (Oxf) 1999, 51(6):701-707.
68. Aittomaki K. The genetics of XX gonadal dysgenesis. Am J Hum Genet 1994, 54(5):844-851.
69. de Zegher F., Jaeken J. Endocrinology of the carbohydrate-deficient glycoprotein syndrome type 1 from birth through adolescence. Pediatr Res 1995, 37(4 Pt 1):395-401.
70. Gelfand I.M., Eugster E.A., DiMeglio L.A. Presentation and clinical progression of pseudohypoparathyroidism with multi-hormone resistance and Albright hereditary osteodystrophy: a case series. J Pediatr 2006, 149(6):877-880.
71. Lee P.A., Houk C.P., Ahmed S.F., et al. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics 2006, 118(2):e488-e500.
72. Michala L., Goswami D., Creighton S.M., et al. Swyer syndrome: presentation and outcomes. BJOG May 2008, 115(6):737-741.
73. Zielinska D., Zajaczek S., Rzepka-Gorska I. Tumors of dysgenetic gonads in Swyer syndrome. J Pediatr Surg 2007, 42(10):1721-1724.
74. Oakes M.B., Eyvazzadeh A.D., Quint E., et al. Complete androgen insensitivity syndrome-a review. J Pediatr Adolesc Gynecol 2008, 21(6):305-310.
75. Sarpel U., Palmer S.K., Dolgin S.E. The incidence of complete androgen insensitivity in girls with inguinal hernias and assessment of screening by vaginal length measurement. J Pediatr Surg 2005, 40(1):133-136. [discussion: 136-7].
76. Costa-Santos M., Kater C.E., Auchus R.J. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J Clin Endocrinol Metab 2004, 89(1):49-60.
77. Yang J., Cui B., Sun S., et al. Phenotype-genotype correlation in eight Chinese 17alpha-hydroxylase/17,20 lyase-deficiency patients with five novel mutations of CYP17A1 gene. J Clin Endocrinol Metab 2006, 91(9):3619-3625.
78. al Kandari H., Katsumata N., Alexander S., et al. Homozygous mutation of P450 side-chain cleavage enzyme gene (CYP11A1) in 46, XY patient with adrenal insufficiency, complete sex reversal, and agenesis of corpus callosum. J Clin Endocrinol Metab 2006, 91(8):2821-2826.
79. Baker B.Y., Lin L., Kim C.J., et al. Nonclassic congenital lipoid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. J Clin Endocrinol Metab 2006, 91(12):4781-4785.
80. Fujieda K., Tajima T., Nakae J., et al. Spontaneous puberty in 46, XX subjects with congenital lipoid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (StAR) gene. J Clin Invest 1997, 99(6):1265-1271.
81. Kaufman F.R., Kogut M.D., Donnell G.N., et al. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med 1981, 304(17):994-998.
82. Prestoz L.L., Couto A.S., Shin Y.S., et al. Altered follicle stimulating hormone isoforms in female galactosaemia patients. Eur J Pediatr 1997, 156(2):116-120.
83. Smith N.M., Byard R.W., Bourne A.J. Testicular regression syndrome-a pathological study of 77 cases. Histopathology 1991, 19(3):269-272.
84. Law H., Mushtaq I., Wingrove K., et al. Histopathological features of testicular regression syndrome: relation to patient age and implications for management. Fetal Pediatr Pathol 2006, 25(2):119-129.
85. Imbeaud S., Rey R., Berta P., et al. Testicular degeneration in three patients with the persistent mullerian duct syndrome. Eur J Pediatr 1995, 154(3):187-190.
86. Vinci G., Anjot M.N., Trivin C., et al. An analysis of the genetic factors involved in testicular descent in a cohort of 14 male patients with anorchia. J Clin Endocrinol Metab 2004, 89(12):6282-6285.
87. Wallace W.H., Thomson A.B., Kelsey T.W. The radiosensitivity of the human oocyte. Hum Reprod 2003, 18(1):117-121.
88. Larsen E.C., Muller J., Schmiegelow K., et al. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 2003, 88(11):5307-5314.
89. Lopez Andreu J.A., Fernandez P.J., Ferris i Tortajada J., et al. Persistent altered spermatogenesis in long-term childhood cancer survivors. Pediatr Hematol Oncol 2000, 17(1):21-30.
90. Shalet S.M., Tsatsoulis A., Whitehead E., et al. Vulnerability of the human Leydig cell to radiation damage is dependent upon age. J Endocrinol 1989, 120(1):161-165.
91. Steffens M., Beauloye V., Brichard B., et al. Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). Clin Endocrinol (Oxf) 2008, 69(5):819-827.
92. Rahhal S.N., Eugster E.A. Unexpected recovery of ovarian function many years after bone marrow transplantation. J Pediatr 2008, 152(2):289-290.
93. Meacham L.R., Ghim T.T., Crocker I.R., et al. Systematic approach for detection of endocrine disorders in children treated for brain tumors. Med Pediatr Oncol 1997, 29(2):86-91.
94. Schatz D.A., Winter W.E. Autoimmune polyglandular syndrome. II: clinical syndrome and treatment. Endocrinol Metab Clin North Am 2002, 31(2):339-352.
95. Wolff A.S., Erichsen M.M., Meager A., et al. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab 2007, 92(2):595-603.
96. Ahonen P., Miettinen A., Perheentupa J. Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. J Clin Endocrinol Metab 1987, 64(3):494-500.
97. Uibo R., Aavik E., Peterson P., et al. Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease. J Clin Endocrinol Metab 1994, 78(2):323-328.
98. Hoek A., Schoemaker J., Drexhage H.A. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997, 18(1):107-134.
99. Buzi F., Badolato R., Mazza C., et al. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome: time to review diagnostic criteria?. J Clin Endocrinol Metab 2003, 88(7):3146-3148.
100. Perniola R., Falorni A., Clemente M.G., et al. Organ-specific and non-organ-specific autoantibodies in children and young adults with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Eur J Endocrinol 2000, 143(4):497-503.
101. Sinisi A.A., D'Apuzzo A., Pasquali D., et al. Antisperm antibodies in prepubertal boys treated with chemotherapy for malignant or non-malignant diseases and in boys with genital tract abnormalities. Int J Androl 1997, 20(1):23-28.
102. Goodpasture J.C., Ghai K., Cara J.F., et al. Potential of gonadotropin-releasing hormone agonists in the diagnosis of pubertal disorders in girls. Clin Obstet Gynecol 1993, 36(3):773-785.
103. Rosenfield R.L., Perovic N., Devine N., et al. Optimizing estrogen replacement treatment in Turner syndrome. Pediatrics 1998, 102(2 Pt 3):486-488.
104. Donaldson M.D., Gault E.J., Tan K.W., et al. Optimising management in Turner syndrome: from infancy to adult transfer. Arch Dis Child 2006, 91(6):513-520.
105. Mauras N., Shulman D., Hsiang H.Y., et al. Metabolic effects of oral versus transdermal estrogen in growth hormone-treated girls with turner syndrome. J Clin Endocrinol Metab 2007, 92(11):4154-4160.
106. Ankarberg-Lindgren C., Elfving M., Wikland K.A., et al. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J Clin Endocrinol Metab 2001, 86(7):3039-3044.
107. Chetkowski R.J., Meldrum D.R., Steingold K.A., et al. Biologic effects of transdermal estradiol. N Engl J Med 1986, 314(25):1615-1620.
108. Nabhan Z.M., DiMeglio L.A., Qi R., et al. Oral versus transdermal estrogen replacement in girls with Turner syndrome: a pilot comparative study. J Clin Endocrinol Metab 2009, 94(6):2009-2014.
109. Piippo S., Lenko H., Kainulainen P., et al. Use of percutaneous estrogen gel for induction of puberty in girls with Turner syndrome. J Clin Endocrinol Metab 2004, 89(7):3241-3247.
110. Richman R.A., Kirsch L.R. Testosterone treatment in adolescent boys with constitutional delay in growth and development. N Engl J Med 1988, 319(24):1563-1567.
111. Soliman A.T., Khadir M.M., Asfour M. Testosterone treatment in adolescent boys with constitutional delay of growth and development. Metabolism 1995, 44(8):1013-1015.
112. Arslanian S., Suprasongsin C. Testosterone treatment in adolescents with delayed puberty: changes in body composition, protein, fat, and glucose metabolism. J Clin Endocrinol Metab 1997, 82(10):3213-3220.
113. Rogol A.D. Pubertal androgen therapy in boys. Pediatr Endocrinol Rev 2005, 2(3):383-390.
114. Kassmann K., Rappaport R., Broyer M. The short-term effect of testosterone on growth in boys on hemodialysis. Clin Nephrol 1992, 37(3):148-154.
115. Mayo A., Macintyre H., Wallace A.M., et al. Transdermal testosterone application: pharmacokinetics and effects on pubertal status, short-term growth, and bone turnover. J Clin Endocrinol Metab 2004, 89(2):681-687.
116. Eiholzer U., Grieser J., Schlumpf M., et al. Clinical effects of treatment for hypogonadism in male adolescents with Prader-Labhart-Willi syndrome. Horm Res 2007, 68(4):178-184.